Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Atezolizumab for Metastatic NSq NSCLC

Dec 7, 2018, 10:13 AM
URL:
On December 6, 2018, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.

Read FDA announcement.

Posted 12/7/2018

Leave a comment